Literature DB >> 17960674

Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol.

Burak Beksaç1, Alejandro González Della Valle, John Anderson, Nigel E Sharrock, Thomas P Sculco, Eduardo A Salvato.   

Abstract

To determine the incidence of thromboembolism after one-stage bilateral total hip arthroplasty and the role of two different chemoprophylaxis agents, we retrospectively studied 644 consecutive patients who underwent one-stage bilateral total hip arthroplasties. All patients received a similar multimodal prophylaxis protocol, which differed only in the postoperative chemoprophylaxis: 292 patients received warfarin (Group 1) and 352 received aspirin (Group 2). All patients were followed for a minimum of 3 months. We observed no difference in the incidence of symptomatic venous thrombosis, pulmonary embolism, or mortality in the two groups. Twenty patients in each group had deep venous thrombosis (7% and 5.7%, respectively) develop. Seven patients (2.39%) in Group 1 and eight (2.27%) in Group 2 had proximal deep venous thrombosis. Four patients in each group had a nonfatal pulmonary embolism (1.36% and 1.13%, respectively). There were two deaths in each group, neither related to venous thromboembolism. One-stage bilateral total hip arthroplasties were associated with a low rate of venous thrombosis and embolism with our multimodal prophylaxis protocol, and we found no difference in the incidence of either in patients who received warfarin or aspirin for chemoprophylaxis. (C) 2007 Lippincott Williams & Wilkins, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17960674

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  6 in total

1.  Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol.

Authors:  Ettore Vulcano; Mark Gesell; Amanda Esposito; Yan Ma; Stavros G Memtsoudis; Alejandro Gonzalez Della Valle
Journal:  Int Orthop       Date:  2012-06-12       Impact factor: 3.075

2.  Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study.

Authors:  Stavros G Memtsoudis; Melanie C Besculides; Licia Gaber; Spencer Liu; Alejandro González Della Valle
Journal:  Int Orthop       Date:  2008-10-17       Impact factor: 3.075

3.  VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.

Authors:  Alejandro González Della Valle; Saurabh Khakharia; Charles J Glueck; Nicole Taveras; Ping Wang; Robert N Fontaine; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-11-26       Impact factor: 4.176

Review 4.  Current issues in thromboprophylaxis in the elderly.

Authors:  Parminder S Chaggar; Kevin S Channer
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions.

Authors:  I Azboy; R Barrack; A M Thomas; F S Haddad; J Parvizi
Journal:  Bone Joint J       Date:  2017-11       Impact factor: 5.082

6.  Thirty-Day Outcomes After Bilateral Total Hip Arthroplasty in a Nationwide Cohort.

Authors:  Jessica S Morton; Benjamin S Kester; Nima Eftekhary; Jonathan Vigdorchik; William J Long; Stavros G Memtsoudis; Lazaros A Poultsides
Journal:  Arthroplast Today       Date:  2020-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.